IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Divisio	onal Application of:		
Andrei LEC	NOV et al.		
Serial No.:	Divisional of 10/191,479	Examiner:	Unassigned
Filed:	October 31, 2003	Group Art Unit:	Unassigned
Title:	METHOD OF PREPARING	LITHIUM COMPLE	X SALTS FOR USE IN

INFORMATION DISCLOSURE STATEMENT <u>UNDER 37 C.F.R. §§ 1.56, 1.97 AND 1.98</u>

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

ELECTROCHEMICAL CELLS

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56,

1.97 a	nd 1.98	as follows:				
TIMIN	G AND	FEES				
\boxtimes		37 C.F.R. § 1.97(b), no fee or statement is required for filing this information sure statement is filed:				
	\boxtimes	within three months of the filing date of a national application other than a CPA under § 1.53(d);				
		within three months of the actual filing date of the national phase of a PCT application; OR				
		before the mailing of a first substantive office action (including after filing of an RCE).				
		37 C.F.R. § 1.97(c), this information disclosure statement is filed after the s specified in 37 C.F.R. § 1.97(b), but before the mailing date of:				
		a final rejection under 37 C.F.R. § 1.113;				
		termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR				
		a notice of allowance under 37 C.F.R. § 1.311; and				
	is accompanied by:					

	the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR
	a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).
	Under 37 C.F.R. § 1.97(d), this information disclosure statement is filed after the mailing date of the following actions which have not been withdrawn:
	a final action under 37 C.F.R. § 1.113;
	termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR
	a notice of allowance under 37 C.F.R. § 1.311;
	AND is filed on or before payment of the issue fee; AND is accompanied by:
	the statement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of \$180.00 under 37 C.F.R. § 1.17(p).
STATI	EMENTS UNDER 37 C.F.R. 1.97(e)
	Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or
	No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.
CITED	MATERIALS
\boxtimes	Copies of materials listed but not attached were cited in benefit (35 U.S.C. § 120) ancestor application Serial No. <u>10/191,479</u> , on Form 892 by the Examiner and/or Form 1449 by the applicant; see 37 C.F.R. § 1.98(d).
	Copies of materials listed but not attached were cited in an international search report dated
\boxtimes	Copies of the materials listed are attached (except for the foregoing).
Non-I	English Language References
	An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).
	A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:

; ÷

X = document of particular relevance when it is taken alone
 Y = document of particular relevance when it is combined with another such

document

A = document defining the general state of the art

O = non-written disclosure

P = intercalated document

T = document cited to understand the theory or principle underlying the invention

E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date

D = cited in the application

L = cited for another reason

& = publication of member of same patent family

Translation of other relevant information on foreign search report

OTHER INFORMATION

None

PAYMENT OF FEES DUE (IF ANY):

A check for \$	covering t	the fee	identified	above is	attached.

Please charge to Deposit Account No. 13-3402 \$_____ for the fee identified above.

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account No. 13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

James F. Ruland, Reg. No. 37,432

Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C.

Arlington Courthouse Plaza 1, Suite 1400

2200 Clarendon Boulevard Arlington, Virginia 22201

Telephone: (703) 243-6333 Facsimile: (703) 243-6410

Attorney Docket No.: MERCK-2125 D2

Date: October 31, 2003
C:\My Forms\Forms\IDS & 1499.doc

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute	for form 1449A/PTC)		Complete if Known		
				Application Number	Divisional of 10/191,479	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	October 31, 2003	
				First Named Inventor	Andrei LEONOV et al.	
				Group Art Unit	Unassigned	
(use as many sheets as necessary)			necessary)	Examiner Name	Unassigned	
Sheet	1	of	1	Attorney Docket Number	MERCK-2125 D2	

	U.S. PATENT DOCUMENTS						
		U.S. Patent Document					
Examiner Initials *	Cite No.1		nd Code² known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY		
	A1	2,486,417		Jackson et al.	11-1949		
	A2	2,877,191		Graydon	03-1959		
	A3	3,395,232		White	07-1968		
	A4	5,468,466		Bacon et al.	11-1995		
	A5	5,670,691		Spangler et al.	09-1997		
	A6	6,441,216		Leonov et al.	08-2002		
	A7						

	FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Office ³	Foreign Patent Docur	ment Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Τ⁵	
	B1								
	B2								

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
	C1	US2001/0033964 A1 PG publication by Heider et al. 10/2001				
	C2	CA:93:124874 abs of Z Anorg Allg Chem by Heller et al., 460, pp. 228-34, 1980				
	C3	CA:128:180516 abs of DE 19633027 2/1998				
	C4 CA:131:47168 abs DE 19757126 6/1999					
	C5	CA:96142944 abs of Liebigs Annalen der Chemie by Hofmann et al. (2), pp. 282-97, 1982				
	C6 CA:117:7597 abs of Bulletin de la Societe Chimique de France by Babin et al. 129(1), pp. 25-28, 1992					
	C7 CA:77:164182 abs of by Kametani et al. (9), pp. 473-4, 1972					
	C8	CA:110:7817 abs of Kagaku to Kogyo by Kishimoto et al. 62(3), pp, 83-5, 1988				

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.